Alnylam Pharmaceuticals, Inc. $ALNY Shares Purchased by Intech Investment Management LLC

Intech Investment Management LLC grew its position in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 703.7% in the 4th quarter, HoldingsChannel.com reports. The fund owned 46,710 shares of the biopharmaceutical company’s stock after purchasing an additional 40,898 shares during the quarter. Intech Investment Management LLC’s holdings in Alnylam Pharmaceuticals were worth $18,574,000 as of its most recent filing with the SEC.

Several other institutional investors have also modified their holdings of ALNY. Geode Capital Management LLC boosted its stake in Alnylam Pharmaceuticals by 6.1% during the 4th quarter. Geode Capital Management LLC now owns 2,650,722 shares of the biopharmaceutical company’s stock valued at $1,056,884,000 after purchasing an additional 151,480 shares during the period. Optimist Retirement Group LLC acquired a new stake in shares of Alnylam Pharmaceuticals in the fourth quarter valued at approximately $383,000. Kestra Investment Management LLC bought a new stake in shares of Alnylam Pharmaceuticals during the fourth quarter valued at approximately $2,391,000. Allstate Corp raised its holdings in shares of Alnylam Pharmaceuticals by 115.0% during the fourth quarter. Allstate Corp now owns 9,829 shares of the biopharmaceutical company’s stock valued at $3,909,000 after buying an additional 5,258 shares during the last quarter. Finally, Legal & General Group Plc boosted its position in shares of Alnylam Pharmaceuticals by 8.3% during the fourth quarter. Legal & General Group Plc now owns 961,496 shares of the biopharmaceutical company’s stock worth $382,339,000 after buying an additional 73,716 shares during the period. Institutional investors own 92.97% of the company’s stock.

Alnylam Pharmaceuticals Stock Performance

ALNY opened at $305.06 on Friday. The business has a 50 day moving average price of $309.63 and a two-hundred day moving average price of $355.11. The company has a debt-to-equity ratio of 0.94, a current ratio of 3.13 and a quick ratio of 3.06. The company has a market capitalization of $40.73 billion, a price-to-earnings ratio of 83.35 and a beta of 0.31. Alnylam Pharmaceuticals, Inc. has a 1-year low of $284.28 and a 1-year high of $495.55.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last issued its quarterly earnings results on Thursday, April 30th. The biopharmaceutical company reported $1.99 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.87 by $1.12. Alnylam Pharmaceuticals had a return on equity of 85.76% and a net margin of 11.72%.The company had revenue of $1.17 billion for the quarter, compared to analysts’ expectations of $1.12 billion. The firm’s revenue for the quarter was up 96.4% on a year-over-year basis. During the same period last year, the firm earned ($0.44) EPS. Research analysts predict that Alnylam Pharmaceuticals, Inc. will post 7.36 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several analysts recently commented on ALNY shares. Chardan Capital restated a “buy” rating and issued a $425.00 target price on shares of Alnylam Pharmaceuticals in a research report on Wednesday, March 25th. Freedom Capital raised Alnylam Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, February 17th. Citigroup started coverage on Alnylam Pharmaceuticals in a report on Tuesday, May 19th. They set a “buy” rating and a $380.00 price target on the stock. Truist Financial cut their price objective on shares of Alnylam Pharmaceuticals from $515.00 to $505.00 and set a “buy” rating on the stock in a research note on Monday, April 13th. Finally, Needham & Company LLC reduced their price objective on shares of Alnylam Pharmaceuticals from $529.00 to $510.00 and set a “buy” rating for the company in a report on Thursday, February 12th. Two research analysts have rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating and six have assigned a Hold rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $463.13.

Insider Activity

In other Alnylam Pharmaceuticals news, EVP Kevin Joseph Fitzgerald sold 1,652 shares of the business’s stock in a transaction dated Tuesday, March 3rd. The shares were sold at an average price of $319.73, for a total value of $528,193.96. Following the sale, the executive vice president directly owned 21,860 shares in the company, valued at approximately $6,989,297.80. The trade was a 7.03% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Jeffrey V. Poulton sold 2,206 shares of the company’s stock in a transaction dated Monday, March 2nd. The shares were sold at an average price of $327.65, for a total transaction of $722,795.90. Following the completion of the sale, the executive vice president directly owned 64,273 shares of the company’s stock, valued at $21,059,048.45. The trade was a 3.32% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 21,255 shares of company stock valued at $6,930,337 over the last quarter. Insiders own 0.86% of the company’s stock.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc (NASDAQ: ALNY) is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.

Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.